PROFESSIONAL PHARMACY GROUP
Specialty Pharmacy

HEPATITIS C VIRUS SPECIALTY CARE PROGRAM

Phone: 844-223-7510
Fax: 844-673-6161

1 PATIENT INFORMATION:

Name: _____
Address: _____
City: _____ State: ____ Zip: _____
Phone: _____ Alt. Phone: _____
Email: _____
DOB: _____ Gender: ❍ M ❍ F Caregiver: _____
Height: _____ Weight: _____ Allergies: _____

2 PRESCRIBER INFORMATION:

Name: _____
Address: _____
City: _____ State: ____ Zip: _____
Phone: _____ Fax: _____
NPI: _____ DEA: _____
Office Contact: _____ Phone: _____
Email: _____

3 STATEMENT OF MEDICAL NECESSITY: (Please Attach All Medical Documentation)

Diagnostic Information

Date of Diagnosis: _____ ICD-10: _____ Race: _____
Genotype: _____ Subtype: _____ Q80K: ❑ Positive ❑ Negative (For Genotype 1a)
Indicate Patient Status: ❑ Naïve ❑ Partial Responder ❑ Non-responder ❑ Null-responder ❑ Relapser
Duration of Previous Therapy: _____ Weeks From: _____ To: _____
Cirrhosis: ❑ No ❑ Yes If Yes: ❑ Compensated ❑ Decompensated
History of Liver Biopsy? ❑ No ❑ Yes If Yes, Please Attach Results
❑ Fibrosure or ❑ Fibroscan: Results: _____
Extra-Hepatic Manifestations: ❑ Ascites ❑ Hepatic Encephalopathy ❑ Thrombocytopenia
❑ Other: _____ Does the patient need liver transplantation? ❑ Yes ❑ No
HBsAg and anti-HBc Test: ❑ Positive ❑ Negative Date: _____

If Prior Authorization is denied, recommended formulary alternatives will be provided to the prescriber based upon the patient's insurance coverage.

Labs

ALT: _____ HGB: _____
AST: _____ HCV RNA: _____
PLT: _____ SrCr: _____
NS5A Resistance Assay: _____ Date: _____

Medication List and Contraindications

❑ Attach Medication List
Is the patient interferon ineligible? ❑ No ❑ Yes
❑ Anxiety ❑ Depression ❑ Pulmonary Abnormalities
❑ Renal Insufficiency ❑ Other: _____

4 INJECTION TRAINING: ❍ Pharmacist to Provide Training ❍ Patient Trained in MD Office ❍ Manufacturer Nurse Support

5 PRODUCT DELIVERY: ❍ Patient's Home ❍ Physician's Office ❍ Pharmacy to Coordinate

6 REQUIRED INFORMATION: Front & back copies of pharmacy & medical cards along with charts & labs from last 90 days

PRESCRIPTION: Duration of Therapy: ❑ 8 Weeks ❑ 12 Weeks ❑ 24 Weeks ❑ Other _____
Patient Name: _____ Patient's Date of Birth: _____

Medication	Dosage & Strength	Direction	QTY	Refills
❑ DAKLINZA™	❑ 30mg Tablets	❑ Take 30mg daily with or without food in combination with Sovaldi® with or without Ribavirin	28	
	❑ 60mg Tablets	❑ Take 60mg daily with or without food in combination with Sovaldi® with or without Ribavirin	28	
	❑ 90mg Tablets	❑ Take 90mg daily with or without food in combination with Sovaldi® with or without Ribavirin	28	
❑ EPCLUSA®	❑ 400/100mg Tablets	❑ Take one tablet daily with or without food	28	
❑ HARVONI®	❑ 90/400mg Tablets	❑ Take one tablet daily with or without food	28	
❑ MAVYRET™	❑ 100/40mg Tablet	❑ Take three tablets orally once daily with food	1 Carton	
❑ OLYSIO®	❑ 150mg Capsules	❑ Take one 150mg capsule orally once a day	28	
❑ SOVALDI®	❑ 400mg Tablets	❑ Take one 400mg tablet orally once a day	28	
❑ VOSEVI®	❑ 400/100/100mg Tablets	❑ Take one tablet orally once daily with food	28	
❑ MODERIBA Dose Pack™ ❑ RIBASPHERE Riba Pack®	❑ 600mg per day ❑ 800mg per day ❑ 1000mg per day ❑ 1200mg per day	❑ Take 200mg tablet every morning/400mg tablet every evening ❑ Take 400mg tablet every morning/400mg tablet every evening ❑ Take 600mg tablet every morning/400mg tablet every evening ❑ Take 600mg tablet every morning/600mg tablet every evening		
❑ MODERIBA™ ❑ RIBASPHERE® ❑ RIBAVIRIN	❑ 200mg Tablets ❑ 200mg Capsules	❑ Take _____ tablets/capsules every morning and, ❑ Take _____ tablets/capsules every evening		
❑ XIFAXAN®	❑ 550mg Tablets	❑ Take one tablet twice daily with or without food	60	
❑ ZEPATIER®	❑ 50/100mg Tablets	❑ Take one tablet daily with or without food	28	
❑ _____	_____	_____		

PRESCRIBER SIGNATURE: I authorize pharmacy to act as my designee for initiating and coordinating insurance prior authorizations, nursing services and patient assistance programs.

Signature: _____ Date: _____ Signature: _____ Date: _____

Substitution Permitted **Dispense As Written**

Prior authorization approval and insurance benefits will be determined by the payor based upon the patient's eligibility, medical necessity, and the terms of the patient's coverage, among other things. Participation in this program is not a guarantee of prior authorization or of payment.